Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study
4 affiliations
- 1Division of Behavioral Sleep Medicine, Iwate Medical University School of Medicine, Shiwa, Japan
- 2Division of Information Sciences, Iwate Medical University, Shiwa, Japan
- 3MSD/ Seimindo Sleep Labo Systems, Morioka, Iwate, Japan
- 4Division of Internal Medicine, Yamaga Clinic, Takeda Healthcare Foundation, Aizu-Wakamatsu, Japan
Abstract
Objectives: Obstructive sleep apnea (OSA) is characterized by systemic inflammation, intermittent hypoxemia, and immune dysregulation and has been associated with increased susceptibility to viral infections. In this study, we aimed to evaluate plasma concentrations of the antimicrobial peptide cathelicidin LL-37 (pLL-37) in individuals with OSA. Methods: The associations between pLL-37 levels, demographic characteristics, and polysomnographic (PSG) parameters were assessed in 58 individuals with OSA and 20 healthy controls. Participants were stratified into two groups stratified by apnea–hypopnea index (AHI): AHI < 15 and AHI ≥ 15. Multiple regression analysis was conducted to identify independent predictors of pLL-37. Results: Significant negative correlations were observed between pLL-37 levels and age, percentage of Stage N1 sleep based on PSG data (%Stage N1), arousal index, AHI, and oxygen desaturation index. Conversely, significant positive correlations were identified between pLL-37 levels and %Stage N3, percentage of rapid eye movement sleep (%Stage REM), mean percentage of peripheral oxygen saturation (%SpO2 mean), and %SpO2 minimum. Mean pLL-37 level was significantly higher in the AHI < 15 group (75.3 ± 29.3 ng/L) than in the AHI ≥ 15 group (47.1 ± 18.3 ng/L). Multiple regression analysis identified %Stage N1 as an independent factor associated with pLL-37. Conclusions: pLL-37 levels were significantly reduced in individuals with severe OSA than in healthy controls. %Stage N1 was independently associated with pLL-37 levels, suggesting a decline with worsening oxygen desaturation. These findings suggest pLL-37 may serve as a biomarker for sleep quality and the severity of impaired oxygenation during sleep with implications for immune vulnerability and infection risk in OSA.
Related
- Predictors of pulmonary embolism in chronic obstructive pulmonary diseases patients admitted for worsening respiratory symptoms: An individual participant data meta-analyses
- Clade B serpins promote direct basal-to-goblet cell differentiation in airways of patients with chronic obstructive pulmonary disease
- Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study
- Mapping antimicrobial stewardship principles in HIV positive patients in sub-Saharan Africa: a systematic scoping review protocol
- Implementation of Clinical Pharmacy Activities in Pediatric Cardiology Department: A French Observational Study
BibTeX
@article{yamaguchi2026plasma,
title = {{Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study}},
author = {Takayuki Yamaguchi and Keisuke Hosokawa and Takenori Mineta and Rie Hosokawa and Shiho Odawara and Rie Chiba and Kazue Asanuma and Setsuko Toyomaki and Mitsuho Sato and Fumiaki Takahashi and Shigeru Sakurai and Kazuhiro Takahashi and Tsuguo Nishijima},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0355855},
url = {https://doi.org/10.1371/journal.pone.0355855},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Plasma levels of antimicrobial peptide LL-37 as a biomarker of sleep quality in patients with obstructive sleep apnea: A clinical observational study
AU - Takayuki Yamaguchi
AU - Keisuke Hosokawa
AU - Takenori Mineta
AU - Rie Hosokawa
AU - Shiho Odawara
AU - Rie Chiba
AU - Kazue Asanuma
AU - Setsuko Toyomaki
AU - Mitsuho Sato
AU - Fumiaki Takahashi
AU - Shigeru Sakurai
AU - Kazuhiro Takahashi
AU - Tsuguo Nishijima
PY - 2026
DA - 2026/09/02
JO - PLOS One
DO - 10.1371/journal.pone.0355855
UR - https://doi.org/10.1371/journal.pone.0355855
AB - Objectives: Obstructive sleep apnea (OSA) is characterized by systemic inflammation, intermittent hypoxemia, and immune dysregulation and has been associated with increased susceptibility to viral infections. In this study, we aimed to evaluate plasma concentrations of the antimicrobial peptide cathelicidin LL-37 (pLL-37) in individuals with OSA. Methods: The associations between pLL-37 levels, demographic characteristics, and polysomnographic (PSG) parameters were assessed in 58 individuals with OSA and 20 healthy controls. Participants were stratified into two groups stratified by apnea–hypopnea index (AHI): AHI < 15 and AHI ≥ 15. Multiple regression analysis was conducted to identify independent predictors of pLL-37. Results: Significant negative correlations were observed between pLL-37 levels and age, percentage of Stage N1 sleep based on PSG data (%Stage N1), arousal index, AHI, and oxygen desaturation index. Conversely, significant positive correlations were identified between pLL-37 levels and %Stage N3, percentage of rapid eye movement sleep (%Stage REM), mean percentage of peripheral oxygen saturation (%SpO2 mean), and %SpO2 minimum. Mean pLL-37 level was significantly higher in the AHI < 15 group (75.3 ± 29.3 ng/L) than in the AHI ≥ 15 group (47.1 ± 18.3 ng/L). Multiple regression analysis identified %Stage N1 as an independent factor associated with pLL-37. Conclusions: pLL-37 levels were significantly reduced in individuals with severe OSA than in healthy controls. %Stage N1 was independently associated with pLL-37 levels, suggesting a decline with worsening oxygen desaturation. These findings suggest pLL-37 may serve as a biomarker for sleep quality and the severity of impaired oxygenation during sleep with implications for immune vulnerability and infection risk in OSA.
SN - 1932-6203
ER -